RGT-61159

RGT-61159 is a small molecule (oral RNA splicing modulator) from Rgenta Therapeutics. An oral small molecule designed to change the splicing of the MYB transcription factor's RNA, which stops production of the cancer-driving MYB protein. Its furthest stage is phase 1, for relapsed or refractory adenoid cystic carcinoma and colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1a/b NCT06462183 (alone and with lenvatinib) active, not recruiting. Company news page lists a release of 22 October 2026 announcing a successful end-of-phase 2 meeting with the FDA and alignment on a phase 3 design in adenoid cystic carcinoma. Whether it works in people has not been established unless a trial below reports it.